Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of DIAMYD MEDICAL B
No Price
Closing Price XSTO 29.04.2026:
1,05 SEK
29.04.2026 15:29
Current Prices from DIAMYD MEDICAL B
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
NASDAQ STOCKHOLM AB
DMYD-B.ST
SEK
29.04.2026 15:29
1,05 SEK
0,03 SEK
+3,33 %
Share Float & Liquidity
Free Float88,58 %
Shares Float118,7 M
Shares Outstanding134 M
Company Profile for DIAMYD MEDICAL B Share
Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase IIb clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is in phase I/II clinical trial for the treatment of autoimmune and type 2 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was incorporated in 1984 and is based in Stockholm, Sweden.
